Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Up 8,549.4% in June

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the recipient of a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 1,073,474 shares, an increase of 8,549.4% from the May 31st total of 12,411 shares. Based on an average daily volume of 24,954 shares, the short-interest ratio is presently 43.0 days.

Innovent Biologics Price Performance

Shares of IVBXF traded down $0.78 during midday trading on Thursday, reaching $9.51. The stock had a trading volume of 2,858 shares, compared to its average volume of 4,899. The company’s 50-day moving average is $10.35 and its 200 day moving average is $10.61. Innovent Biologics has a 12-month low of $9.10 and a 12-month high of $15.12.

Innovent Biologics Company Profile

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).